Trial Profile
A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2022
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Abdominal aortic aneurysm
- Focus Therapeutic Use
- Acronyms INFORAAA
- Sponsors Faron Pharmaceuticals
- 03 Feb 2022 Results published in the Faron Pharmaceuticals Media Release.
- 03 Feb 2022 According to a Faron Pharmaceuticals media release, results from this study were published in the multidisciplinary journal Scientific Reports from the Nature Publishing Group.
- 05 Dec 2019 Status changed from recruiting to discontinued.